Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children

A Prospective, Multicenter, Open-label, Non-comparative Study of Safety and Efficacy of Synagis in Children at High Risk of Severe Respiratory Syncytial Virus Infection in the Russian Federation

Sponsors

Lead Sponsor: Abbott

Source Abbott
Brief Summary

100 Russian children of 2 years of age and less in high-risk populations (preterm, and/or with heart and lung problems) will receive palivizumab (Synagis) 15 mg/kg intramuscularly as prophylaxis to severe respiratory syncytial virus (RSV) infection in order to study the safety and efficacy of the drug in Russian subjects.

Detailed Description

A prospective, multicenter, open-label, non-comparative study of safety and efficacy of palivizumab (Synagis) 15 mg/kg intramuscularly as prophylaxis to severe lower respiratory tract respiratory syncytial virus infection in 100 Russian children of 2 years of age and less in high-risk populations (preterm infants [less than or equal to 35 weeks gestational age], infants with bronchopulmonary dysplasia [BPD], and infants with hemodynamically significant congenital heart disease [HSCHD]).

Overall Status Completed
Start Date 2009-11-01
Completion Date 2010-07-01
Primary Completion Date 2010-04-01
Phase Phase 2/Phase 3
Study Type Interventional
Primary Outcome
Measure Time Frame
Frequency of Adverse Events Through 30 days following the last injection of palivizumab
Number of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Through 30 days following the last injection of palivizumab
Secondary Outcome
Measure Time Frame
Total Number of RSV Hospitalization Days Through 30 days following the last injection of palivizumab
Total RSV Hospitalization Days With Increased Supplemental Oxygen Requirement Through 30 days following the last injection of palivizumab
Number of Intensive Care Unit (ICU) Admissions During RSV Hospitalization Through 30 days following the last injection of palivizumab
Total Days of RSV ICU Stay Through 30 days following the last injection of palivizumab
Number of Subjects Who Received Mechanical Ventilation During RSV Hospitalization Through 30 days following the last injection of palivizumab
Total Days of Mechanical Ventilation During RSV Hospitalization Through 30 days following the last injection of palivizumab
Enrollment 100
Condition
Intervention

Intervention Type: Biological

Intervention Name: palivizumab

Description: palivizumab 15 mg/kg intramuscularly

Arm Group Label: palivizumab

Eligibility

Criteria:

Inclusion Criteria: Subjects must meet all of the following criteria to be enrolled into the study: 1. Infants at high risk of severe RSV infection defined as fulfilling at least one of the following: - Infants born at less than or equal to 35 weeks gestational age AND are less than or equal to 6 months of age at enrollment - Infants less than or equal to 24 months of age at enrollment AND with a diagnosis of bronchopulmonary dysplasia (defined as oxygen requirement at a corrected gestational age of 36 weeks) requiring intervention/management (i.e., oxygen, diuretics, bronchodilators, corticosteroids, etc.) anytime within 6 months prior to enrollment - Infants less than or equal to 24 months of age at enrollment with hemodynamically significant congenital heart disease, either cyanotic or acyanotic, unoperated or partially corrected. Children with acyanotic cardiac lesions must have pulmonary hypertension (greater than or equal to 40 mmHg measured pressure in the pulmonary artery [ultrasound acceptable]) or the need for daily medication to manage congenital heart disease. Children with the following conditions are not eligible: hemodynamically insignificant small atrial or ventricular septal defects, patent ductus arteriosis, children with aortic stenosis, pulmonic stenosis, or coarctation of the aorta alone. 2. Informed Consent Form signed by parent(s). Exclusion Criteria: Subjects meeting any of the following criteria are not eligible for the study: 1. Hospitalization at the time of enrollment (unless discharge is anticipated within 14 days). 2. Mechanical ventilation (including continuous positive airway pressure [CPAP]) at the time of enrollment. 3. Life expectancy less than 6 months. 4. Active respiratory illness, or other acute infection. 5. Known renal impairment, as determined by the investigator. 6. Known hepatic impairment, as determined by the investigator. 7. History of seizures (except neonatal seizures). 8. Unstable neurological disorder (includes, but is not restricted to, epilepsy and decompensated hydrocephaly). 9. Known immunodeficiency, as determined by the investigator. 10. Allergy to immunoglobulin products. 11. Prior receipt of RSV vaccine or prophylaxis (e.g., palivizumab or motavizumab), or administration of a product possibly containing RSV-neutralizing antibody within 100 days prior to enrollment (includes, but is not restricted to, the following: RSV hyperimmunoglobulin, polyclonal intravenous immunoglobulin, cytomegalovirus hyperimmunoglobulin, varicella zoster hyperimmunoglobulin). 12. Participation in another clinical trial within 30 days prior to enrollment. 13. Previous enrollment in this trial. 14. For any reason, subject is considered by the investigator to be an unsuitable candidate for this study.

Gender:

All

Minimum Age:

N/A

Maximum Age:

2 Years

Healthy Volunteers:

No

Overall Official
Last Name Role Affiliation
Konstantin M Gudkov, MD Study Director Abbott
Location
Facility:
Site Ref # / Investigator 22699 | Ivanovo, 153731, Russian Federation
Site Ref # / Investigator 22694 | Kazan, 420012, Russian Federation
Site Ref # / Investigator 24022 | Moscow, 117198, Russian Federation
Site Ref # / Investigator 15744 | Moscow, 117931, Russian Federation
Site Ref # / Investigator 15745 | Moscow, 117997, Russian Federation
Site Ref # / Investigator 24025 | Moscow, 117997, Russian Federation
Site Ref # / Investigator 15781 | Moscow, 119991, Russian Federation
Site Ref # / Investigator 22686 | Moscow, 119991, Russian Federation
Site Ref # / Investigator 15747 | Moscow, 125412, Russian Federation
Site Ref # / Investigator 22696 | Novosibirsk, 630091, Russian Federation
Site Ref # / Investigator 24023 | Novosibirsk, 630091, Russian Federation
Site Ref # / Investigator 22692 | Saint Petersburg, 193312, Russian Federation
Site Ref # / Investigator 22683 | Saint Petersburg, 194100, Russian Federation
Site Ref # / Investigator 22693 | Saint Petersburg, 194291, Russian Federation
Site Ref # / Investigator 22685 | Saint Petersburg, 196650, Russian Federation
Site Ref # / Investigator 15722 | Saint Petersburg, 197022, Russian Federation
Site Ref # / Investigator 15748 | Saint Petersburg, 198205, Russian Federation
Site Ref # / Investigator 15782 | Saint Petersburg, 198205, Russian Federation
Site Ref # / Investigator 15746 | Tomsk, 634012, Russian Federation
Location Countries

Russian Federation

Verification Date

2011-06-01

Responsible Party

Name Title: Konstantin Gudkov, Clinical Research Project Manager

Organization: Abbott Laboratories LLC Russia

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: palivizumab

Type: Experimental

Description: palivizumab 15 mg/kg intramuscularly every 30 days for 3 to 5 injections

Study Design Info

Allocation: Non-Randomized

Intervention Model: Single Group Assignment

Primary Purpose: Prevention

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News